Current systemic therapies are severely lacking for cutaneous T cell lymphomas, says Cecilia Larocca, MD. Clinical trials are essential in finding much needed new therapies for CTCL. Dr. Larocca reviews why these studies are important, who should be included in the trials, and what trials are underway.
Editorially independent coverage supported by SkinAlliance and EltaMD. Practical Dermatology's coverage of the 2019 AAD Annual Meeting is not endorsed by or affiliated with the American Academy of Dermatology (AAD).